Anti-fibrotic activity of oligonol is most likely due to its capacity to suppress the HSC activation by lessening hepatic inflammation via inhibition of NF-κB activation in the early stages of liver fibrosis and restoring the balance of oxidative status via Nrf2 activation, which prevents lipid peroxidation and ROS production. This evidence concerns the gene NFKB1 and Hepatic fibrosis.